HRP20161236T1 - Kompozicija kaspofugina - Google Patents

Kompozicija kaspofugina Download PDF

Info

Publication number
HRP20161236T1
HRP20161236T1 HRP20161236TT HRP20161236T HRP20161236T1 HR P20161236 T1 HRP20161236 T1 HR P20161236T1 HR P20161236T T HRP20161236T T HR P20161236TT HR P20161236 T HRP20161236 T HR P20161236T HR P20161236 T1 HRP20161236 T1 HR P20161236T1
Authority
HR
Croatia
Prior art keywords
caspofungin
pharmaceutically acceptable
mixture according
formulation
excipients
Prior art date
Application number
HRP20161236TT
Other languages
English (en)
Croatian (hr)
Inventor
Swapnil P. Shirode
Piysh Patel
Atul Patil
Suresh Gidwani
Neil Parikh
Anita Bevetek Mocnik
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of HRP20161236T1 publication Critical patent/HRP20161236T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20161236TT 2010-09-20 2011-09-19 Kompozicija kaspofugina HRP20161236T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38433310P 2010-09-20 2010-09-20
PCT/EP2011/066202 WO2012038371A1 (en) 2010-09-20 2011-09-19 Caspofungin composition
EP11761049.3A EP2618814B1 (en) 2010-09-20 2011-09-19 Caspofungin composition

Publications (1)

Publication Number Publication Date
HRP20161236T1 true HRP20161236T1 (hr) 2016-11-18

Family

ID=44677877

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161236TT HRP20161236T1 (hr) 2010-09-20 2011-09-19 Kompozicija kaspofugina

Country Status (20)

Country Link
US (2) US20120101030A1 (enExample)
EP (1) EP2618814B1 (enExample)
JP (1) JP5914486B2 (enExample)
KR (1) KR20130136466A (enExample)
CN (1) CN103118663A (enExample)
AU (1) AU2011304408B2 (enExample)
CA (1) CA2810112A1 (enExample)
DK (1) DK2618814T3 (enExample)
ES (1) ES2593727T3 (enExample)
HR (1) HRP20161236T1 (enExample)
HU (1) HUE030464T2 (enExample)
IL (1) IL225339A0 (enExample)
MX (1) MX2013003045A (enExample)
PL (1) PL2618814T3 (enExample)
PT (1) PT2618814T (enExample)
RS (1) RS55216B1 (enExample)
RU (1) RU2013114993A (enExample)
UA (1) UA111599C2 (enExample)
WO (1) WO2012038371A1 (enExample)
ZA (1) ZA201302113B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103212058A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲剂的组合物
CN103212059A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲液的组合物
SI2922530T1 (sl) * 2012-11-20 2017-04-26 Fresenius Kabi Usa, Llc Formulacije kaspofugin acetata
CN103142997A (zh) * 2013-03-13 2013-06-12 浙江海正药业股份有限公司 含有抗真菌剂和琥珀酸盐缓冲液的药物组合物
KR20140123782A (ko) * 2013-04-15 2014-10-23 에스케이케미칼주식회사 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물
CN104116716A (zh) * 2013-04-25 2014-10-29 四川海思科制药有限公司 一种含卡泊芬净的冻干粉针剂药物组合物
WO2015052115A1 (en) * 2013-10-07 2015-04-16 Galenicum Health S.L. Stable pharmaceutical formulations of caspofungin
GR1008818B (el) * 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
CN108760937B (zh) * 2018-07-27 2020-12-29 杭州华东医药集团新药研究院有限公司 醋酸卡泊芬净中残留乙二胺的测定及其应用
CN109758426B (zh) * 2019-01-24 2021-04-27 四川制药制剂有限公司 一种注射用醋酸卡泊芬净药物组合物及其制备方法
CN110859950B (zh) * 2019-11-25 2021-08-10 武汉大学 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用
EP4364566A1 (en) * 2022-11-04 2024-05-08 B. Braun Melsungen AG Anti-fungal composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7673991A (en) * 1990-03-30 1991-10-30 Smithkline Beecham Corporation Method for treating fungal infection
JP2930823B2 (ja) 1991-12-11 1999-08-09 株式会社東芝 X線ctスキャナ用検出器及びx線検出装置用シンチレータチャネルセパレータ
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US20080046580A1 (en) 2006-06-29 2008-02-21 Nokia Corporation Account creation system and call processing system
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
HRP20130109T4 (hr) * 2006-07-26 2016-05-20 Sandoz Ag Formulacije kaspofungina
JP5537425B2 (ja) 2007-06-26 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 凍結乾燥抗真菌組成物
EP2285236A1 (en) * 2008-05-30 2011-02-23 DSM IP Assets B.V. Use of succinic acid
KR20110011704A (ko) 2008-06-25 2011-02-08 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 카스포펀진 불순물 a를 함유하지 않는 카스포펀진

Also Published As

Publication number Publication date
PT2618814T (pt) 2016-10-06
DK2618814T3 (en) 2016-10-10
US20120101030A1 (en) 2012-04-26
ES2593727T3 (es) 2016-12-12
US20150072923A1 (en) 2015-03-12
CA2810112A1 (en) 2012-03-29
JP5914486B2 (ja) 2016-05-11
MX2013003045A (es) 2013-06-24
RS55216B1 (sr) 2017-02-28
WO2012038371A1 (en) 2012-03-29
RU2013114993A (ru) 2014-10-27
AU2011304408B2 (en) 2015-01-15
UA111599C2 (uk) 2016-05-25
ZA201302113B (en) 2014-05-28
EP2618814A1 (en) 2013-07-31
KR20130136466A (ko) 2013-12-12
JP2013537212A (ja) 2013-09-30
US9393307B2 (en) 2016-07-19
EP2618814B1 (en) 2016-07-27
PL2618814T3 (pl) 2017-01-31
IL225339A0 (en) 2013-06-27
CN103118663A (zh) 2013-05-22
HUE030464T2 (en) 2017-05-29
AU2011304408A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
HRP20161236T1 (hr) Kompozicija kaspofugina
JP2013537212A5 (enExample)
CA2753641C (en) Bendamustine cyclopolysaccharide compositions
CN102614491B (zh) 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
US9937122B2 (en) Palonosetron oral transmucosal film or patch
WO2013112762A4 (en) Bendamustine compositions and methods therefore
IL270818B1 (en) A particle and a medical preparation containing an insoluble compotecin substance having a double core-shell structure and a method for making the same
JP5723031B2 (ja) エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物
CA2715832A1 (en) Topotecan ready to use solutions
US20110207764A1 (en) Cyclopolysaccharide compositions
KR101889878B1 (ko) 적하 가능한 안과용 비마토프로스트 겔
WO2017073798A1 (ja) 鼻粘膜投与用医薬組成物
WO2022083729A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
WO2014102731A1 (en) Novel pharmaceutical compositions of romidepsin
CN104043103B (zh) 一种多黏菌素e甲磺酸钠冻干制剂及其制备方法
CN101474164A (zh) 一种口服复方紫杉醇胶囊剂及制备方法
CN102988280B (zh) 一种加雷沙星滴眼剂
WO2012029076A3 (en) Stable pharmaceutical composition
CN103211755A (zh) 无菌稳定的阿奇霉素滴眼液的生产方法
CN102614493B (zh) 一种含有棘白菌素类抗真菌剂卡泊芬净的液体药用组合物
CN100453077C (zh) 含藤黄酸的可注射胶束制剂及其制备方法
WO2008089709A3 (en) Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer
CN103462906B (zh) 一种注射用多西他赛纳米粒及其制备方法
CN104116706A (zh) 一种丙酮酸乙酯滴眼液及其制备方法